Nivolumab combined with hypofractionated stereotactic irradiation (HFSRT) for patients with recurrent high grade gliomas: A phase I trial (NCT02829931).
Sahebjam S, Forsyth P, Arrington J, Tran N, Jaglal M, Mokhtari S, Long W, Macaulay R, Wicklund M, Drury-Sibiga A, Gatewood T, Robinson T, Raval R, Yu M. Nivolumab combined with hypofractionated stereotactic irradiation (HFSRT) for patients with recurrent high grade gliomas: A phase I trial (NCT02829931). Journal Of Clinical Oncology 2017, 35: tps2084-tps2084. DOI: 10.1200/jco.2017.35.15_suppl.tps2084.Peer-Reviewed Original ResearchHigh-grade gliomasPhase I trialGrade gliomasI trialPD-1PD-L1Grade IIIAnti-PD-1/PD-L1 blockadePD-1/PD-L1 blockadeRecurrent high-grade gliomaOngoing phase I trialDose-expansion cohortsPD-L1 blockadePrior radiation therapyTolerability of nivolumabGroup of patientsImmune checkpoint pathwaysLimited treatment optionsPreliminary antitumor activityOrthotopic murine modelLong-term survivalPrimary study objectiveIgG4 monoclonal antibodyNivolumab monotherapySafety cohort